Tizona Therapeutics is a privately held immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune disorders. Its lead program is an anti-CCR4 monoclonal antibody intended to deplete regulatory T cells and is expected to enter the clinic in 2017. The company also advances IL-35 programs targeting an immunosuppressive cytokine to reverse tumor immune suppression and potentially treat autoimmune disease. Proceeds from financing will be used to advance these immunotherapy programs and the broader pipeline. Tizona was co-founded by prominent translational research and immunotherapy leaders who serve as scientific founders and advisors. The company is based in South San Francisco and has raised more than $70 million through its Series A and B financings.

Total raised

$43M

Funding rounds

1

Latest round

Series B

Latest activity

Mar 2016